TY - JOUR
T1 - Proteomic approach to identify biomarkers for invasive cervix cancer - a prospective pilot study
AU - Mysona, D.
AU - Pyrzak, A.
AU - Allen, J.
AU - Powell, M.
AU - Kleven, D.
AU - Zhi, W.
AU - Sharma, A.
AU - Bai, S.
AU - She, Jin Xiong
AU - Rungruang, B.
AU - Ghamande, S.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.
AB - Purpose of Investigation: Cervical cancer (CC) is the second most common cancer of women worldwide and a leading cause of mortality. Unfortunately, this disease has no current viable serum biomarkers capable of diagnosing CC or predicting prognosis. The present authors' objective was to examine novel serum biomarkers capable of identifying patients with invasive CC and determine their utility in monitoring disease status. Materials and Methods: In this IRB approved prospective study, luminex bead array was used to measure 18 different serum protein concentrations in CC patients (n=23), women with precancerous lesions (CIN2-3) (n=20) and patients with normal cervical cytology (n=20). CC patients had blood samples drawn within 30 days of diagnosis and repeat samples post-completion of therapy. MMP7 expression was confirmed by immunohistochemistry (IHC) and scored independently by two pathologists. Results: Multiple proteins had different levels in CC, controls, and CIN (p < 0.05). MMP7 was most promising for identifying invasive cancer (sensitivity of 88.9%, specificity 95%, p < 0.001). IHC confirmed MMP7 expression in invasive CC. MMP7 serum levels were an indicator for progression-free survival (PFS) (HR 3.82, CI: 1.10-13.29, p = 0.025) and overall survival (OS) (HR 7.96, CI: 0.91-69.32, p = 0.03). Conclusion: MMP7 serum concentration was altered when comparing CC, controls, and CIN2-3, and shows potential as being a future biomarker for both identifying invasive CC and patient prognosis. Based on this study, MMP7 warrants further investigation as a biomarker of invasive CC.
KW - Biomarkers
KW - Cervical cancer
KW - Serum proteomics
UR - http://www.scopus.com/inward/record.url?scp=85053324228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053324228&partnerID=8YFLogxK
U2 - 10.12892/ejgo4357.2018
DO - 10.12892/ejgo4357.2018
M3 - Article
AN - SCOPUS:85053324228
SN - 0392-2936
VL - 39
SP - 737
EP - 742
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
IS - 5
ER -
